SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Yang, Y. Articles by Sanderson, R. D. Search for Related Content PubMed PubMed Citation Articles by Yang, Y. Articles by Sanderson, R. D. Related Collections Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 July 2002, Vol. 100, No. 2, pp. 610-617 NEOPLASIA Soluble syndecan-1 promotes growth of myeloma tumors in vivo Yang Yang, Shmuel Yaccoby, Wei Liu, J. Kevin Langford, Carla Y. Pumphrey, Allison Theus, Joshua Epstein, and Ralph D. Sanderson From the Arkansas Cancer Research Center, Departments of Pathology and Anatomy & Neurobiology, and the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock. Syndecan-1 (CD138) is a transmembrane heparan sulfate-bearing proteoglycan expressed by most myeloma plasma cells that regulates adhesion, migration, and growth factor activity. In patients with myeloma, shed syndecan-1 accumulates in the bone marrow, and high levels of syndecan-1 in the serum are an indicator of poor prognosis. To test the effect of soluble syndecan-1 on tumor cell growth and dissemination, ARH-77 B-lymphoid cells were engineered to produce a soluble form of syndecan-1. Controls included vector only (neo)-transfected cells and cells transfected with full-length syndecan-1 complementary DNA that codes for the cell surface form of syndecan-1. Assays reveal that all 3 transfectants have similar growth rates in vitro, but cells expressing soluble syndecan-1 are hyperinvasive in collagen gels relative to controls. When injected into the marrow of human bones that were implanted in severe combined immunodeficient mice, tumors formed by cells expressing soluble syndecan-1 grow faster than tumors formed by neo-transfected cells or by cells expressing cell surface syndecan-1. In addition, cells bearing cell surface syndecan-1 exhibit a diminished capacity to establish tumors within the mice as compared with both neo- and soluble syndecan-1-transfected cells. Tumor cell dissemination to a contralateral human bone is detected significantly more often in the tumors producing soluble syndecan-1 than in controls. Thus, high levels of soluble syndecan-1 present in patients with myeloma may contribute directly to the growth and dissemination of the malignant cells and thus to poor prognosis. © 2002 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: K. Hayashida, Y. Chen, A. H. Bartlett, and P. W. Park Syndecan-1 Is an in Vivo Suppressor of Gram-positive Toxic Shock J. Biol. Chem., July 18, 2008; 283(29): 19895 - 19903. [Abstract] [Full Text] [PDF] Y. Yang, V. MacLeod, Y. Dai, Y. Khotskaya-Sample, Z. Shriver, G. Venkataraman, R. Sasisekharan, A. Naggi, G. Torri, B. Casu, et al. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy Blood, September 15, 2007; 110(6): 2041 - 2048. [Abstract] [Full Text] [PDF] K. Mahtouk, D. Hose, P. Raynaud, M. Hundemer, M. Jourdan, E. Jourdan, V. Pantesco, M. Baudard, J. De Vos, M. Larroque, et al. Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma Blood, June 1, 2007; 109(11): 4914 - 4923. [Abstract] [Full Text] [PDF] G. Su, S. A. Blaine, D. Qiao, and A. Friedl Shedding of Syndecan-1 by Stromal Fibroblasts Stimulates Human Breast Cancer Cell Proliferation via FGF2 Activation J. Biol. Chem., May 18, 2007; 282(20): 14906 - 14915. [Abstract] [Full Text] [PDF] Y. Yang, V. MacLeod, H.-Q. Miao, A. Theus, F. Zhan, J. D. Shaughnessy Jr., J. Sawyer, J.-P. Li, E. Zcharia, I. Vlodavsky, et al. Heparanase Enhances Syndecan-1 Shedding: A NOVEL MECHANISM FOR STIMULATION OF TUMOR GROWTH AND METASTASIS J. Biol. Chem., May 4, 2007; 282(18): 13326 - 13333. [Abstract] [Full Text] [PDF] C. Y. Fears, C. L. Gladson, and A. Woods Syndecan-2 Is Expressed in the Microvasculature of Gliomas and Regulates Angiogenic Processes in Microvascular Endothelial Cells J. Biol. Chem., May 26, 2006; 281(21): 14533 - 14536. [Abstract] [Full Text] [PDF] S. B. Selleck Shedding Light on the Distinct Functions of Proteoglycans Sci. Signal., April 4, 2006; 2006(329): pe17 - pe17. [Abstract] [Full Text] [PDF] Y. Dai, Y. Yang, V. MacLeod, X. Yue, A. C. Rapraeger, Z. Shriver, G. Venkataraman, R. Sasisekharan, and R. D. Sanderson HSulf-1 and HSulf-2 Are Potent Inhibitors of Myeloma Tumor Growth in Vivo J. Biol. Chem., December 2, 2005; 280(48): 40066 - 40073. [Abstract] [Full Text] [PDF] K. Ding, M. Lopez-Burks, J. A. Sanchez-Duran, M. Korc, and A. D. Lander Growth factor-induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cells J. Cell Biol., November 21, 2005; 171(4): 729 - 738. [Abstract] [Full Text] [PDF] Y. Yang, V. MacLeod, M. Bendre, Y. Huang, A. M. Theus, H.-Q. Miao, P. Kussie, S. Yaccoby, J. Epstein, L. J. Suva, et al. Heparanase promotes the spontaneous metastasis of myeloma cells to bone Blood, February 1, 2005; 105(3): 1303 - 1309. [Abstract] [Full Text] [PDF] J. Reiland, R. D. Sanderson, M. Waguespack, S. A. Barker, R. Long, D. D. Carson, and D. Marchetti Heparanase Degrades Syndecan-1 and Perlecan Heparan Sulfate: FUNCTIONAL IMPLICATIONS FOR TUMOR CELL INVASION J. Biol. Chem., February 27, 2004; 279(9): 8047 - 8055. [Abstract] [Full Text] [PDF] T. Maeda, C. M. Alexander, and A. Friedl Induction of Syndecan-1 Expression in Stromal Fibroblasts Promotes Proliferation of Human Breast Cancer Cells Cancer Res., January 15, 2004; 64(2): 612 - 621. [Abstract] [Full Text] [PDF] T. Kelly, H.-Q. Miao, Y. Yang, E. Navarro, P. Kussie, Y. Huang, V. MacLeod, J. Casciano, L. Joseph, F. Zhan, et al. High Heparanase Activity in Multiple Myeloma Is Associated with Elevated Microvessel Density Cancer Res., December 15, 2003; 63(24): 8749 - 8756. [Abstract] [Full Text] [PDF] G. H. Underhill, K. P. Kolli, and G. S. Kansas Complexity within the plasma cell compartment of mice deficient in both E- and P-selectin: implications for plasma cell differentiation Blood, December 1, 2003; 102(12): 4076 - 4083. [Abstract] [Full Text] [PDF] K. Asosingh, H. De Raeve, I. Van Riet, B. Van Camp, and K. Vanderkerken Multiple myeloma tumor progression in the 5T2MM murine model is a multistage and dynamic process of differentiation, proliferation, invasion, and apoptosis Blood, April 15, 2003; 101(8): 3136 - 3141. [Abstract] [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020